Page 140 - 2022_01-Haematologica-web

Y. Zaimoku et al.
References
1. Young NS. Aplastic anemia. N Engl J Med. 2018;379(17):1643-1656.
2. Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;129(11):1428-1436.
3. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012;120 (6):1185-1196.
4. Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immuno- suppression for aplastic anemia. N Engl J Med. 2017;376(16):1540-1550.
5. Peffault de Latour R, Marsh J, Iacobelli S, et al. Results of the EBMT SAAWP phase III prospective randomized multicenter RACE study of horse ATG and ciclosporin with or without eltrombopag in naïve SAA patients [abstract]. In: 46th Annual Meeting of the EBMT. 2020 Aug 31-Sep 1; Virtual: 2020. Abstract O018.
6. Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367(1):11-19.
7. Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinu- ation of drug. Blood. 2014;123(12):1818- 1825.
8. Assi R, Garcia-Manero G, Ravandi F, et al. Addition of eltrombopag to immunosup- pressive therapy in patients with newly diagnosed aplastic anemia. Cancer. 2018;124(21):4192-4201.
9.Lengline E, Drenou B, Peterlin P, et al. Nationwide survey on the use of eltrom- bopag in patients with severe aplastic ane- mia: a report on behalf of the French Reference Center for Aplastic Anemia. Haematologica. 2018;103(2):212-220.
10. Lee JW, Lee SE, Jung CW, et al. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treat- ment phase 2 trial. Lancet Haematol. 2019;6(11):e562-e572.
11. Ecsedi M, Lengline É, Knol-Bout C, et al. Use of eltrombopag in aplastic anemia in Europe. Ann Hematol. 2019;98(6):1341-1350.
12. Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol. 2009;144(2):206- 216.
13. Afable MG 2nd, Shaik M, Sugimoto Y, et al. Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. Haematologica. 2011;96(9):1269-1275.
14. Shin SH, Yoon JH, Yahng SA, et al. The effi- cacy of rabbit antithymocyte globulin with cyclosporine in comparison to horse antithymocyte globulin as a first-line treat- ment in adult patients with severe aplastic anemia: a single-center retrospective study. Ann Hematol. 2013;92(6):817-824.
15. Narita A, Muramatsu H, Sekiya Y, et al. Paroxysmal nocturnal hemoglobinuria and telomere length predicts response to immunosuppressive therapy in pediatric aplastic anemia. Haematologica. 2015;100 (12):1546-1552.
16.Elmahdi S, Muramatsu H, Narita A, et al. Markedly high plasma thrombopoietin (TPO) level is a predictor of poor response to immunosuppressive therapy in children with acquired severe aplastic anemia. Pediatr Blood Cancer. 2016;63(4):659-664.
17. Vaht K, Goransson M, Carlson K, et al. Low response rate to ATG-based immuno-
suppressive therapy in very severe aplastic anaemia - a Swedish nationwide cohort study. Eur J Haematol. 2018;100(6):613- 620.
18. Cabannes-Hamy A, Boissel N, Peffault De Latour R, et al. The effect of age in patients with acquired aplastic anaemia treated with immunosuppressive therapy: comparison of Adolescents and Young Adults with children and older adults. Br J Haematol. 2018;183(5):766-774.
19. Chang MH, Kim KH, Kim HS, et al. Predictors of response to immunosuppres- sive therapy with antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severe aplastic ane- mia. Eur J Haematol. 2010;84(2):154-159.
20. Zhao X, Zhang L, Jing L, et al. The role of paroxysmal nocturnal hemoglobinuria clones in response to immunosuppressive therapy of patients with severe aplastic ane- mia. Ann Hematol. 2015;94(7):1105-1110.
21. Yoshida N, Yagasaki H, Hama A, et al. Predicting response to immunosuppressive therapy in childhood aplastic anemia. Haematologica. 2011;96(5):771-774.
22. Boddu P, Garcia-Manero G, Ravandi F, et al. Clinical outcomes in adult patients with aplastic anemia: a single institution experi- ence. Am J Hematol. 2017;92(12):1295-1302.
23. Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med. 2015;373(1):35-47.
24. Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55-CD59- blood cells pre- dicts response to immunosuppressive thera- py and prognosis in patients with aplastic anemia. Blood. 2006;107(4):1308-1314.
25.Kulagin A, Lisukov I, Ivanova M, et al. Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anaemia patients treated with combined immunosuppression: results of two-centre prospective study. Br J Haematol. 2014;164 (4):546-554.
26. Sakaguchi H, Nishio N, Hama A, et al. Peripheral blood lymphocyte telomere length as a predictor of response to immunosuppressive therapy in childhood aplastic anemia. Haematologica. 2014;99(8): 1312-1316.
27. Kordasti S, Costantini B, Seidl T, et al. Deep phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment. Blood. 2016;128(9):1193-1205.
28. Zaimoku Y, Patel BA, Kajigaya S, et al. Deficit of CD19+ CD24hi CD38hi regulato- ry B cells in severe aplastic anaemia. Br J Haematol. 2020;190(4):610-617.
29. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003;289 (9):1130-1135.
30. Scheinberg P, Nunez O, Wu C, Young NS. Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymo- cyte globulin, ciclosporin and mycopheno- late mofetil. Br J Haematol. 2006;133(6):606- 611.
31.Scheinberg P, Wu CO, Nunez O, Boss C, Sloand EM, Young NS. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica. 2009;94(3):348-354.
32. Scheinberg P, Nunez O, Weinstein B,
Biancotto A, Wu CO, Young NS. Horse ver- sus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365(5):430-438.
33. Feng X, Scheinberg P, Wu CO, et al. Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syn- dromes. Haematologica. 2011;96(4):602- 606.
34. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical sta- tistics. Bone Marrow Transplant. 2013;48(3): 452-458.
35. Bacigalupo A, Brand R, Oneto R, et al. Treatment of acquired severe aplastic ane- mia: bone marrow transplantation com- pared with immunosuppressive therapy-- the European Group for Blood and Marrow Transplantation experience. Semin Hematol. 2000;37(1):69-80.
36. Yoshida N, Kobayashi R, Yabe H, et al. First- line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosup- pressive therapy. Haematologica. 2014;99 (12):1784-1791.
37. Schrezenmeier H, Griesshammer M, Hornkohl A, et al. Thrombopoietin serum levels in patients with aplastic anaemia: cor- relation with platelet count and persistent elevation in remission. Br J Haematol. 1998;100(3):571-576.
38. Zhao X, Feng X, Wu Z, et al. Persistent ele- vation of plasma thrombopoietin levels after treatment in severe aplastic anemia. Exp Hematol. 2018;58:39-43.
39. Dunn DE, Tanawattanacharoen P, Boccuni P, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med. 1999;131(6): 401-408.
40. Katagiri T, Sato-Otsubo A, Kashiwase K, et al. Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood. 2011;118 (25):6601-6609.
41. Zaimoku Y, Takamatsu H, Hosomichi K, et al. Identification of an HLA class I allele closely involved in the autoantigen presenta- tion in acquired aplastic anemia. Blood. 2017;129(21):2908-2916.
42.Babushok DV, Duke JL, Xie HM, et al. Somatic HLA mutations expose the role of class I-mediated autoimmunity in aplastic anemia and its clonal complications. Blood Adv. 2017;1(22):1900-1910.
43. Katagiri T, Kawamoto H, Nakakuki T, et al. Individual hematopoietic stem cells in human bone marrow of patients with aplas- tic anemia or myelodysplastic syndrome stably give rise to limited cell lineages. Stem Cells. 2013;31(3):536-546.
44. Maruyama H, Katagiri T, Kashiwase K, et al. Clinical significance and origin of leukocytes that lack HLA-A allele expression in patients with acquired aplastic anemia. Exp Hematol. 2016;44(10):931-939.
45. Lee-Six H, Obro NF, Shepherd MS, et al. Population dynamics of normal human blood inferred from somatic mutations. Nature. 2018;561(7724):473-478.
46.Admiraal R, van Kesteren C, Jol-van der Zijde CM, et al. Association between anti- thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multi- centre, retrospective pharmacodynamic cohort analysis. Lancet Haematol. 2015;2(5): e194-203.
47. Admiraal R, Nierkens S, de Witte MA, et al. Association between anti-thymocyte globu-
132
haematologica | 2022; 107(1)